37.31
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
What drives Cytokinetics Incorporated stock priceRapid portfolio appreciation - Autocar Professional
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Cytokinetics Incorporated Stock Analysis and ForecastUnbelievable profit margins - jammulinksnews.com
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
What analysts say about Cytokinetics Incorporated stockRapid wealth creation - jammulinksnews.com
Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards 220,000 Shares in Employee Stock Grants at $38.68 Strike Price - Stock Titan
Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks
Cytokinetics CEO Makes a Significant Stock Move! - TipRanks
Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com Australia
Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com South Africa
Why Cytokinetics Incorporated stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Cytokinetics Incorporated stock price move sharplyDaily Swing Candidates - Newser
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times
Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Quiver Quantitative
Major Clinical Trial Results: Cytokinetics Reveals New Aficamten Data vs Metoprolol in HCM Treatment - Stock Titan
Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Cytokinetics (CYTK): Balancing Optimism and Caution in Aficamten's High-Stakes Journey - AInvest
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress - Yahoo.co
11 Best Most Active Stocks To Buy According to Analysts - Insider Monkey
Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth? - Smartkarma
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus
Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan
Cytokinetics CEO Robert Blum sells $169,000 in stock By Investing.com - Investing.com Canada
Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook By Investing.com - Investing.com India
Cytokinetics’ SWOT analysis: aficamten’s promise drives stock outlook - Investing.com
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program | CYTK Stock News - GuruFocus
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program - The Manila Times
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):